HUGH SWEENEY

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket
    H L Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 273:6262-70. 1998
  2. ncbi Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function
    H L Sweeney
    Department of Physiology, A700 Richards Building, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6085, USA
    Proc Natl Acad Sci U S A 95:14406-10. 1998
  3. ncbi Regulation of asymmetric smooth muscle myosin II molecules
    H L Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6085, USA
    J Biol Chem 275:41273-7. 2000
  4. ncbi What can myosin VI do in cells?
    H Lee Sweeney
    Department of Physiology University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104 6085 USA
    Curr Opin Cell Biol 19:57-66. 2007
  5. ncbi Structural and functional insights into the Myosin motor mechanism
    H Lee Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6085, USA
    Annu Rev Biophys 39:539-57. 2010
  6. ncbi Myosin VI rewrites the rules for myosin motors
    H Lee Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, B700 Richards Building, 3700 Hamilton Walk, Philadelphia, PA 19104 6085, USA
    Cell 141:573-82. 2010
  7. ncbi Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice
    Kevin J Morine
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e9176. 2010
  8. ncbi Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells
    Gary P Kobinger
    Gene Therapy Program, Division of Medical Genetics, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
    Hum Gene Ther 14:1441-9. 2003
  9. ncbi Diaphragm displays early and progressive functional deficits in dysferlin-deficient mice
    Elisabeth R Barton
    Department of Anatomy and Cell Biology, School of Dental Medicine, 441A Levy Building, 240 S 40th Street, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Muscle Nerve 42:22-9. 2010
  10. ncbi Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure
    Vasant Jayasankar
    Department of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Card Surg 20:93-101. 2005

Research Grants

  1. Structure and Function of Myosin VI
    HUGH LEE SWEENEY; Fiscal Year: 2010
  2. MYOSIN ISOZYMES
    HUGH LEE SWEENEY; Fiscal Year: 2010
  3. Structure and Function of Myosin VI
    HUGH SWEENEY; Fiscal Year: 2006
  4. Muscle: Contractile Proteins GRC 2005
    HUGH SWEENEY; Fiscal Year: 2005
  5. BIOENGINEERING RESEARCH PARTNERSHIP--MUSCULAR DYSTROPHY
    HUGH SWEENEY; Fiscal Year: 2004
  6. Understanding and Preventing Disuse Atrophy
    HUGH SWEENEY; Fiscal Year: 2007
  7. MYOSIN ISOZYMES
    HUGH SWEENEY; Fiscal Year: 2007
  8. MYOSIN ISOZYMES
    HUGH SWEENEY; Fiscal Year: 2009
  9. Structure and Function of Myosin VI
    HUGH SWEENEY; Fiscal Year: 2007
  10. New Directions in Biology and Disease of Skeletal Muscle
    HUGH SWEENEY; Fiscal Year: 2003

Collaborators

Detail Information

Publications43

  1. ncbi Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket
    H L Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 273:6262-70. 1998
    ..In addition, the rate of ATP hydrolysis is slowed...
  2. ncbi Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function
    H L Sweeney
    Department of Physiology, A700 Richards Building, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6085, USA
    Proc Natl Acad Sci U S A 95:14406-10. 1998
    ..Furthermore, these data suggest that these TnT mutations may cause disease via an increased energetic load on the heart. This would represent a second paradigm for HCM pathogenesis...
  3. ncbi Regulation of asymmetric smooth muscle myosin II molecules
    H L Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6085, USA
    J Biol Chem 275:41273-7. 2000
    ..This may be part of the mechanism underlying "latch" in smooth muscle...
  4. ncbi What can myosin VI do in cells?
    H Lee Sweeney
    Department of Physiology University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104 6085 USA
    Curr Opin Cell Biol 19:57-66. 2007
    ..These mechanistic insights allow us to speculate on how unusual aspects of myosin VI structure and function allow it to fill unique niches in cells...
  5. ncbi Structural and functional insights into the Myosin motor mechanism
    H Lee Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6085, USA
    Annu Rev Biophys 39:539-57. 2010
    ..We also describe studies that delineate how some classes of myosin motors are adapted for processive movement on actin...
  6. ncbi Myosin VI rewrites the rules for myosin motors
    H Lee Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, B700 Richards Building, 3700 Hamilton Walk, Philadelphia, PA 19104 6085, USA
    Cell 141:573-82. 2010
    ..Given that other classes of myosins may share some of these features, understanding the design principles of myosin VI will help guide the study of the functions of myosins that adopt similar strategies...
  7. ncbi Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice
    Kevin J Morine
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e9176. 2010
    ..Previously described approaches to blocking myostatin signaling include injection delivery of inhibitory propeptide domain or neutralizing antibodies...
  8. ncbi Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells
    Gary P Kobinger
    Gene Therapy Program, Division of Medical Genetics, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
    Hum Gene Ther 14:1441-9. 2003
    ..This study shows that progenitor cells can be genetically engineered in vivo and subsequently proliferate into terminally differentiated tissue carrying the genetic graft in a way that stably corrects function...
  9. ncbi Diaphragm displays early and progressive functional deficits in dysferlin-deficient mice
    Elisabeth R Barton
    Department of Anatomy and Cell Biology, School of Dental Medicine, 441A Levy Building, 240 S 40th Street, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Muscle Nerve 42:22-9. 2010
    ..These studies show that, unlike limb muscles, the diaphragm from the A/J mouse displays early deficits in function that may lower the age needed for evaluating potential therapies for dysferlinopathies...
  10. ncbi Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure
    Vasant Jayasankar
    Department of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Card Surg 20:93-101. 2005
    ..This technique may be useful to treat or prevent postinfarction heart failure...
  11. ncbi Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model
    Lawrence T Bish
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e10230. 2010
    ..Myostatin is a negative regulator of cardiac growth, and further studies are warranted to investigate the role of myostatin in the healthy and failing heart...
  12. ncbi Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy
    Y Joseph Woo
    Division of Cardiothoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Thorac Cardiovasc Surg 130:321-9. 2005
    ....
  13. ncbi Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy
    Kevin J Morine
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Muscle Nerve 42:722-30. 2010
    ..No effect on heart mass or function was observed. Our results indicate that activin IIB receptor blockade represents a novel and effective therapeutic strategy for the muscular dystrophies...
  14. ncbi Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat
    Lawrence T Bish
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Hum Gene Ther 19:1359-68. 2008
    ..AAV9 should be used in rodent cardiac studies and may be the vector of choice for clinical trials of cardiac gene transfer...
  15. ncbi Gene therapy in large animal models of human cardiovascular genetic disease
    Meg M Sleeper
    Department of Clinical Studies, University of Pennsylvania Veterinary School, Philadelphia, PA, USA
    ILAR J 50:199-205. 2009
    ..g., calcium metabolism, apoptosis) could normalize diseased myocardial function. Gene therapy may offer a promising new approach for the treatment of cardiac disease in both veterinary and human clinical settings...
  16. ncbi Status of therapeutic gene transfer to treat canine dilated cardiomyopathy in dogs
    Meg M Sleeper
    Department of Clinical Studies, University of Pennsylvania Veterinary School, Philadelphia, PA 19104, USA
    Vet Clin North Am Small Anim Pract 40:717-24. 2010
    ..The authors are currently evaluating this approach to treat canine idiopathic dilated cardiomyopathy...
  17. ncbi The motor mechanism of myosin V: insights for muscle contraction
    H Lee Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, A700 Richards Building, 3700 Hamilton Walk, Philadelphia, PA 19104 6085, USA
    Philos Trans R Soc Lond B Biol Sci 359:1829-41. 2004
    ....
  18. ncbi Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain
    Subhasis Chatterjee
    Division of Cardiothoracic Surgery and Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Thorac Cardiovasc Surg 125:1461-9. 2003
    ..Adenovirus-apoptosis repressor with caspase recruitment domain administration offers a potential strategy after myocardial ischemia to protect the heart from late postischemic cardiomyopathy...
  19. ncbi One year transgene expression with adeno-associated virus cardiac gene transfer
    Y Joseph Woo
    University of Pennsylvania Department of Surgery, Philadelphia, PA 19104, United States
    Int J Cardiol 100:421-6. 2005
    ..This study examined the feasibility of AAV-mediated myocardial gene transfer in mice, the animal which, because of transgenic technology, has become the disease model of choice for cardiovascular research...
  20. ncbi Gene doping
    H Lee Sweeney
    University of Pennsylvania School of Medicine, USA
    Sci Am 291:62-9. 2004
  21. ncbi Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure
    Subhasis Chatterjee
    Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Circulation 106:I212-7. 2002
    ..The benefit at 6 weeks is postulated to result from a Bcl-2-mediated reduction in apoptosis and ventricular remodeling. Adeno-Bcl-2 administration offers a potential strategy to protect the heart from late postischemic heart failure...
  22. ncbi Calcium functionally uncouples the heads of myosin VI
    Carl A Morris
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6085, USA
    J Biol Chem 278:23324-30. 2003
    ..Lastly, calmodulin mutants reveal that the calcium effect is dependent on calcium binding to the N-terminal lobe of calmodulin...
  23. ncbi How myosin VI coordinates its heads during processive movement
    H Lee Sweeney
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    EMBO J 26:2682-92. 2007
    ..While this mechanism is unlike that of any other myosin superfamily member, it bears remarkable similarities to that of another processive motor from a different superfamily--kinesin I...
  24. ncbi Functional role of loop 2 in myosin V
    Christopher M Yengo
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6085, USA
    Biochemistry 43:2605-12. 2004
    ..The ability to maintain a high affinity for actin in the weak binding states may prevent diffusion away from the actin filament and increase the degree of processive motion of myosin V...
  25. ncbi Leupeptin-based inhibitors do not improve the mdx phenotype
    Joshua Selsby
    Department of Physiology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Am J Physiol Regul Integr Comp Physiol 299:R1192-201. 2010
    ....
  26. ncbi Kinetic characterization of the weak binding states of myosin V
    Christopher M Yengo
    University of Pennsylvania School of Medicine, Department of Physiology and Pennsylvania Muscle Institute, Philadelphia, Pennsylvania 19104, USA
    Biochemistry 41:8508-17. 2002
    ....
  27. ncbi Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy
    Pavan Atluri
    Division of Cardiothoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Ann Thorac Surg 81:1728-36. 2006
    ....
  28. ncbi Kinetic mechanism of blebbistatin inhibition of nonmuscle myosin IIb
    Bhagavathi Ramamurthy
    Department of Physiology, University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, Pennsylvania 19104-6085, USA
    Biochemistry 43:14832-9. 2004
    ..These effects are likely mediated by binding of blebbistatin within the myosin cleft that progressively closes in forming the acto-myosin rigor state...
  29. ncbi Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice
    Elisabeth R Barton
    Department of Physiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Cell Biol 157:137-48. 2002
    ..These results suggest that a combination of promoting muscle regenerative capacity and preventing muscle necrosis could be an effective treatment for the secondary symptoms caused by the primary loss of dystrophin...
  30. ncbi Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy
    Vasant Jayasankar
    Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA
    Circulation 110:II180-6. 2004
    ..The reduction in myocardial fibrosis may be primarily responsible for the improved diastolic function in treated animals. TIMP-1 overexpression is a promising therapeutic target for continued investigation...
  31. ncbi Attenuation of skeletal muscle atrophy via protease inhibition
    Carl A Morris
    Dept. of Physiology and the Pennsylvania Muscle Institute, Univ. of Pennsylvania School of Medicine, A-700 Richards Bldg, 3700 Hamilton Walk, Philadelphia, PA 19104-6085, USA
    J Appl Physiol 99:1719-27. 2005
    ..Thus BBI is a candidate therapeutic agent to minimize skeletal muscle atrophy and loss of strength associated with disuse, cachexia, sepsis, weightlessness, or the combination of age and inactivity...
  32. ncbi Adhesion-contractile balance in myocyte differentiation
    Maureen A Griffin
    Biophysical Engineering Laboratory, 112 Towne Building, and Pennsylvania Muscle Institute, University of Pennsylvania, D-700 Richards Building, 3700 Hamilton Walk, Philadelphia, PA 19104, USA
    J Cell Sci 117:5855-63. 2004
    ..Myotubes in culture are thus clearly prestressed by myosin II, and this contractility couples to substrate compliance and ultimately influences actomyosin striation...
  33. ncbi Cargo binding induces dimerization of myosin VI
    Denis Phichith
    Department of Physiology, University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104 6085, USA
    Proc Natl Acad Sci U S A 106:17320-4. 2009
    ..Because, unexpectedly, a monomeric fragment of Dab2 triggers dimerization, it would appear that myosin VI is designed to function as a dimer in cells...
  34. ncbi gamma-Sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesion
    Maureen A Griffin
    Pennsylvania Muscle Institute, University of Pennsylvania Medical Center, D 700 Richards Building, 3700 Hamilton Walk, Philadelphia, PA 19104 6083, USA
    J Cell Sci 118:1405-16. 2005
    ..We conclude that gammaSG normally moderates contractile prestress in skeletal muscle, and we propose a role for gammaSG in membrane-based signaling of the effects of prestress and sarcomerogenesis...
  35. ncbi Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure
    Vasant Jayasankar
    Department of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Pliladelphia, PA 19104, USA
    Circulation 108:II230-6. 2003
    ..This therapy may be useful as an adjunct or alternative to standard revascularization techniques in patients with ischemic heart failure...
  36. ncbi Myosin VI dimerization triggers an unfolding of a three-helix bundle in order to extend its reach
    Monalisa Mukherjea
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Mol Cell 35:305-15. 2009
    ..This unconventional mechanism generates an extension of the lever arm of myosin VI...
  37. ncbi Patterning, prestress, and peeling dynamics of myocytes
    Maureen A Griffin
    Department of Chemical and Biomolecular Engineering, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Biophys J 86:1209-22. 2004
    ....
  38. ncbi Fructose 1,6-diphosphate administration attenuates post-ischemic ventricular dysfunction
    Jeffrey E Cohen
    University of Pennsylvania, School of Medicine, Department of Surgery, Philadelphia, PA 19104, USA
    Heart Lung Circ 15:119-23. 2006
    ..0369). CONCLUSIONS: The administration of the glycolytic intermediate, FDP, by intravenous injection, resulted in significantly improved myocardial function after ischemia and improved bioenergetics during ischemia...
  39. ncbi Mutation of smooth muscle myosin causes epithelial invasion and cystic expansion of the zebrafish intestine
    Kenneth N Wallace
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Dev Cell 8:717-26. 2005
    ..Furthermore, they suggest that high-throughput screens to identify regulators of cancer cell invasion may be feasible in zebrafish...
  40. ncbi Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments
    Adam J Engler
    School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Cell Biol 166:877-87. 2004
    ..These findings have major implications for in vivo introduction of stem cells into diseased or damaged striated muscle of altered mechanical composition...
  41. ncbi Molecular extensibility of mini-dystrophins and a dystrophin rod construct
    Nishant Bhasin
    Pennsylvania Muscle Institute and Graduate Groups in Physics and Cell and Molecular Biology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Mol Biol 352:795-806. 2005
    ..The results thus reveal new modes of dystrophin flexibility that may prove central to functions of both dystrophin and mini-dystrophins...
  42. ncbi Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling
    Mark F Berry
    Department of Surgery, Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Heart Lung Transplant 23:1061-8. 2004
    ..05) and the relaxation time constant (14.6 +/- 0.6 vs 17.9 +/- 1.2 msec; p < 0.05). CONCLUSIONS: TNF inhibition after infarction reduced leukocyte infiltration and extracellular matrix turnover and preserved cardiac function...
  43. ncbi Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance
    Mark F Berry
    Division of Cardiothoracic Surgery, Department of Physiology, University of Pennsylvania School of Medicine, A700 Richards Bldg, 3700 Hamilton Walk, Philadelphia, PA 19104-6085, USA
    Am J Physiol Heart Circ Physiol 290:H2196-203. 2006
    ..Improving scarred heart muscle compliance could be a functional benefit of cellular cardiomyoplasty...

Research Grants48

  1. Structure and Function of Myosin VI
    HUGH LEE SWEENEY; Fiscal Year: 2010
    ..We propose that the regulated dimerization obviates the need to regulate motor activity. ..
  2. MYOSIN ISOZYMES
    HUGH LEE SWEENEY; Fiscal Year: 2010
    ....
  3. Structure and Function of Myosin VI
    HUGH SWEENEY; Fiscal Year: 2006
    ..determine which kinetic and structural features are necessary for processive movement and the large step size of myosin VI; and 3) delineate putative modes of regulation of the myosin VI motor. ..
  4. Muscle: Contractile Proteins GRC 2005
    HUGH SWEENEY; Fiscal Year: 2005
    ..This will be a transitional conference in that the overall focus of the conference will be divided between the Molecular Basis of Muscle Contraction and the broader topic of the Design and Function of Molecular Motors. ..
  5. BIOENGINEERING RESEARCH PARTNERSHIP--MUSCULAR DYSTROPHY
    HUGH SWEENEY; Fiscal Year: 2004
    ..Lee Sweeney, Ph.D.); and Section 3: development of non-invasive methods for monitoring therapeutic benefits of dystrophin gene transfer (directed by Glenn Walter, Ph.D.). ..
  6. Understanding and Preventing Disuse Atrophy
    HUGH SWEENEY; Fiscal Year: 2007
    ..abstract_text> ..
  7. MYOSIN ISOZYMES
    HUGH SWEENEY; Fiscal Year: 2007
    ....
  8. MYOSIN ISOZYMES
    HUGH SWEENEY; Fiscal Year: 2009
    ....
  9. Structure and Function of Myosin VI
    HUGH SWEENEY; Fiscal Year: 2007
    ..We propose that the regulated dimerization obviates the need to regulate motor activity. ..
  10. New Directions in Biology and Disease of Skeletal Muscle
    HUGH SWEENEY; Fiscal Year: 2003
    ..Its foci on cellular and molecular aspects of skeletal muscle as they relate to health, disease and dysfunction should bring together researchers who do not often attend the same meetings. ..
  11. PHYSIOLOGY AND MYOSIN ISOZYMES OF SKELETAL MUSCLE FIBERS
    HUGH SWEENEY; Fiscal Year: 1993
    ..Plasticity is relevant not only to normal adaptation to altered activity but also to adaptation that occurs in neuromuscular disease states...
  12. CORE--PROTEIN ENGINEERING
    HUGH SWEENEY; Fiscal Year: 2002
    ..In addition, proteins will be through a combination of heterologous expression using either baculovirus/SF9 cells or E. coli and through the purification of proteins from rabbit tissues. ..
  13. TRAINING IN MUSCLE BIOLOGY
    HUGH SWEENEY; Fiscal Year: 2003
    ..This is evidenced by the many prominent scientists around the world, who have trained in this field at the University of Pennsylvania. ..
  14. MYOSIN ISOZYMES
    HUGH SWEENEY; Fiscal Year: 2003
    ..In this manner we will begin to dissect the functional and structural domains of the myosin motor, within the framework of delineating the principles of myosin design and isoform diversity. ..
  15. IN VIVO STUDIES OF TROPONIN T FUNCTION
    HUGH SWEENEY; Fiscal Year: 2002
    ..Our findings will provide fundamental knowledge of the mechanisms of muscle contraction and a basis for development of gene and drug therapies for the treatment of HCM. ..